105.61 USD
▼-4.86-4.40%
盘后 105.63 +0.02%
2026-09-15
市值
$1.50B
市盈率
—
EPS
-8.88
股息率
—
52 周区间
26.19 – 155.29
成交量
251.60K
Beta
3.67
目标价
266.67
52W 低 26.1952W 高 155.29
价格走势
公司简介
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung canc...